Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PPM1B | O75688 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9133786 | 1.00 | CHRM2 (0.53) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL9133791 | 1.00 | CHRM2 (0.53) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL272354 | 0.94 | CHRM2 (0.48) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL8058857 | 0.94 | CHRM2 (0.48) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL13595131 | 0.94 | CHRM2 (0.48) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL11514730 | 0.94 | CHRM2 (0.48) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL28866489 | 0.92 | CHRM2 (0.47) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL28527891 | 0.92 | SLC6A2 (0.50) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL17816439 | 0.91 | CHRM2 (0.47) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL2983239 | 0.91 | CHRM2 (0.47) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117776829-A | Method for continuously preparing amine compound | 上海巽田科技股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-108658762-B | Synthesis method of alicyclic o-diester | 浙江凯普化工有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-7371747-B2 | Cyanoalkylamino derivatives as protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2008-05-13 | — | — | US | disclosed |
| EP-1446115-B1 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | disclosed |
| EP-1446115-A4 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-02-02 | — | — | EP | disclosed |
| US-20050014941-A1 | Cyanoalkylamino derivatives as protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-01-20 | — | — | US | disclosed |
| EP-1446115-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-08-18 | — | — | EP | disclosed |
| EP-0952997-B1 | POLYMERIZATION OF OLEFINS | DU PONT (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6613915-B1 | Nickel (II) complexes of certain monoanionic bidentate ligands; pyrrole-2-imine ligand intermediate | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-09-02 | — | — | US | disclosed |
| WO-2003041649-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-05-22 | — | — | WO | disclosed |
| US-6174975-B1 | ADDITION POLYMERIZATION, CATALYSTS AND COORDINATION COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY | 2001-01-16 | — | — | US | disclosed |
| EP-0952997-A1 | POLYMERIZATION OF OLEFINS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-11-03 | — | — | EP | disclosed |
| WO-1998030609-A1 | POLYMERIZATION OF OLEFINS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-07-16 | — | — | WO | disclosed |
| US-5414016-A | New leukotriene-B4 derivatives, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014941-A1 | Cyanoalkylamino derivatives as protease inhibitors | CTSB, CTSK, CTSS | CHRM2 4167/4885CHRM4 4398/4885CHRM3 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.